ATX-II-induced pulmonary vein arrhythmogenesis related to atrial fibrillation and long QT syndrome

European Journal of Clinical Investigation
Yen-Yu LuYi-Jen Chen

Abstract

Long QT syndrome (LQTS) is associated with a high incidence of atrial fibrillation (AF), but the underlying mechanisms are unclear. Pulmonary veins (PVs) play a critical role in AF genesis. Type 3 LQTS increases late sodium current (I(Na,L) ), which may increase PV arrhythmogenesis and AF. Therefore, this study examines PV arrhythmogenesis in anemonia sulcata toxin II (ATX-II)-induced type 3 LQTS and evaluates whether the I(Na,L) inhibitor ranolazine can suppress PV arrhythmogenesis. Conventional microelectrodes were used to record the action potentials (AP) and contractility in isolated rabbit PV specimens before and after ATX-II administration with or without ranolazine. Anemonia sulcata toxin II (100 nM) increased the PV spontaneous rates from 2·0 ± 0·1 to 2·9 ± 0·2 Hz (n = 7), induced PV burst firing (100%) with the genesis of early afterdepolarization (EAD) (86%) and prolonged the AP duration. Ranolazine (0·1, 1 and 10 μM) dose dependently reduced the PV spontaneous rates from 2·5 ± 0·2 to 2·3 ± 0·2 Hz, 1·9 ± 0·2 and 1·5 ± 0·3 Hz (P < 0·05) and decreased the diastolic tension by 40 ± 19%, 87 ± 26% and 113 ± 28%. In the presence of ranolazine (10 μM), ATX-II (100 nM) further increased the AP duration. However, ATX-II neithe...Continue Reading

References

Apr 15, 1996·Annals of the New York Academy of Sciences·D M BersR A Bassani
May 1, 1997·Current Opinion in Cardiology·Q WangJ A Towbin
Sep 3, 1998·The New England Journal of Medicine·M HaïssaguerreJ Clémenty
Mar 20, 2004·The Journal of Pharmacology and Experimental Therapeutics·Lin WuLuiz Belardinelli
Jul 10, 2004·Journal of Cardiovascular Pharmacology·Yejia SongLuiz Belardinelli
Apr 21, 2005·Heart Rhythm : the Official Journal of the Heart Rhythm Society·David J TesterMichael J Ackerman
Apr 12, 2006·Pacing and Clinical Electrophysiology : PACE·Alexander Burashnikov, Charles Antzelevitch
May 1, 2007·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Serge SicouriCharles Antzelevitch
Oct 2, 2007·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Wanwarang WongcharoenShih-Ann Chen
May 3, 2008·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Jonathan N JohnsonMichael J Ackerman
Jul 5, 2008·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Serge SicouriCharles Antzelevitch
Oct 22, 2008·Journal of the American College of Cardiology·Takeru MakiyamaMinoru Horie
Oct 22, 2008·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Begoña BenitoJosep Brugada
Nov 20, 2008·Journal of Cardiovascular Electrophysiology·Stephan ZellerhoffPaulus Kirchhof
Apr 9, 2009·Progress in Biophysics and Molecular Biology·Jingjing WuMing Lei
Aug 25, 2009·American Journal of Physiology. Heart and Circulatory Physiology·Yejia SongLuiz Belardinelli
Dec 3, 2009·Circulation. Arrhythmia and Electrophysiology·Serge SicouriCharles Antzelevitch
Aug 24, 2010·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Andreas BlanaLarissa Fabritz
Jun 16, 2011·Cardiovascular Research·Marc D LemoineStanley Nattel
Jun 21, 2011·Life Sciences·Kazuyoshi SuenariShih-Ann Chen

❮ Previous
Next ❯

Citations

Feb 5, 2013·Journal of Cardiovascular Electrophysiology·Carlo Napolitano
Jun 14, 2016·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Andres EnriquezAdrian Baranchuk
May 20, 2017·Journal of the American Heart Association·Guizhi LiuGan-Xin Yan
Oct 23, 2019·Clinical and Experimental Pharmacology & Physiology·Yen-Yu LuYi-Jen Chen
May 7, 2020·Frontiers in Pharmacology·Balázs HorváthTamás Bányász

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Related Papers

Heart Rhythm : the Official Journal of the Heart Rhythm Society
Andreas BlanaLarissa Fabritz
Heart Rhythm : the Official Journal of the Heart Rhythm Society
Ahmad S Amin, Zahurul A Bhuiyan
Heart Rhythm : the Official Journal of the Heart Rhythm Society
Serge SicouriCharles Antzelevitch
The Journal of Pharmacology and Experimental Therapeutics
Serge SicouriCharles Antzelevitch
Journal of Cardiovascular Electrophysiology
Serge SicouriCharles Antzelevitch
© 2022 Meta ULC. All rights reserved